BL Melanis
- Biotech or pharma, therapeutic R&D
BL Melanis is an early-stage biotech based in Pangyo, South Korea, focused on developing first-in-class molecular glue degraders (MGDs) to dismantle tumor-specific survival mechanisms in aggressive cancers. ML301 targets ALT-positive, telomerase-independent tumors (~10% of cancers, incl. osteosarcoma and pancreatic NETs) by degrading a novel ALT-essential protein (F1) identified via CRISPR screening. ML302 targets a lineage-survival factor (S1) critical in mantle cell lymphoma (MCL), showing synergy with BTK inhibitors and potential to overcome BTKi resistance. The company’s dual-platform—PHENOGLUE (phenotypic MGD screen) and DELGLUE (DEL-based E3 ligase targeting)—supports rapid hit ID and optimization. BL Melanis partners with leading CROs and academic labs to advance precision oncology programs with strong scientific and commercial potential.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}